 previous article in this issue | next article in this issue  |
|
Document Details : Title: Selecting an appropriate and reimbursed anti-osteoporotic treatment option: a practical tool in the Belgian setting Author(s): GROOTAERT V, DE KEULENAER J, BOONEN S, SERMON A, SPRIET I, WILLEMS L Journal: Acta Clinica Belgica Volume: 67 Issue: 1 Date: 2012 Pages: 13-18 DOI: 10.2143/ACB.67.1.1003037 Abstract : Osteoporosis is a highly prevalent and often undertreated disease in the elderly. Osteoporosis-related fractures are associated with signifi cant morbidity and mortality. Anti-osteoporotic drugs are only reimbursed by the Belgian government if strict conditions are fulfi lled. The aim of this paper was to create a practical tool to guide the physician and other health care professionals to make an appropriate choice. Two fl owcharts, based on Belgian reimbursement criteria and literature review were developed. Both tools provide an overview of the reimbursed pharmacological agents in the management of osteoporosis in male and female subjects |
